Introduction Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma
viral oncogene homolog B) mutations, including V600E and other types. Vemurafenib …

Introduction BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations are
identified in approximately 2% of non-small cell lung cancer (NSCLC). Because of the rarity …

Introduction Mutant BRAF is a driver oncogene found in 2% of lung adenocarcinomas and
represents a target for therapy. We examined the clinical characteristics and course of …

BRAF mutations are seen in up to 3.5–4% of the non-small cell lung cancer (NSCLC)
patients. BRAF V600E mutations account for 50% of these cases, and the remaining BRAF …

Purpose BRAF mutations occur in non–small-cell lung cancer. Therapies targeting BRAF
mutant tumors have recently been identified. We undertook this study to determine the …

Purpose: BRAF mutations are divided into functional classes distinguished by signaling
mechanism and kinase activity: V600-mutant kinase-activating monomers (class I), kinase …

Objectives Targeted therapies in non-small cell lung cancer (NSCLC) now also include
inhibitors against mutated BRAF. We present clinicopathological characteristics of nearly …

Inhibitors targeting active protein kinases, such as EGFR or ALK, have demonstrated
significant efficacy in the treatment of lung cancer. Activating mutations in the MAPK …

Background BRAF is a proto-oncogene encoding a serine/threonine protein kinase which
promotes cell proliferation and survival. BRAF mutations are commonly seen in melanoma …

Background: Several subsets of non–small-cell lung cancer (NSCLC) are defined by
molecular alterations acting as tumor drivers, some of them being currently therapeutically …